Lung cancer trial seeks immune clues before surgery
NCT ID NCT05206812
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study gives the immunotherapy drug durvalumab to people with operable non-small cell lung cancer before their surgery. The main goal is to see how the drug changes the tumor and immune system, not to cure the disease. About 25 adults with stage IIA to IIIB lung cancer will take part. The results will help researchers understand immune responses better.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yonsei University Health System, Severance Hospital
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?